Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

Inhibitors of poly(ADP‐ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In our study, of 182 women with EOC treated with PARPi, 16 (8.7%...

Descripción completa

Detalles Bibliográficos
Autores principales: Todisco, Elisabetta, Gigli, Federica, Ronchini, Chiara, Amato, Viviana, Sammassimo, Simona, Pastano, Rocco, Parma, Gabriella, Lapresa, Maria Teresa, Bertolini, Francesco, Corsini, Chiara, Gregato, Giuliana, Poletti, Claudia, Pelicci, Pier Giuseppe, Alcalay, Myriam, Colombo, Nicoletta, Tarella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Ejemplares similares